Answers are grounded in this paper and cite their sources.
Paclitaxel (PTX) is a widely used anti-tumor drug in cancer therapy. However, its poor water solubility restricts its application in therapeutic procedures. Furthermore, the Cremophor® in the formulation can cause various side effects, leading to non-specific drug distribution in tumors and normal tissues. To overcome these limitations, researchers have explored numerous drug delivery systems to enhance the solubility of PTX and achieve targeted delivery. One such strategy involves using polymer nanoparticles, tiny particles composed of polymers that encapsulate and stabilize PTX, thereby improving its solubility and bioavailability. In addition, these polymer nanoparticles can enhance the therapeutic effect of PTX through passive targeting and active targeting mechanisms. This review first highlights the challenges of paclitaxel in current applications, focusing on current synthetic advances in PTX and drug resistance; subsequently, various approaches to deliver PTX using polymer Nanoparticles are discussed. Finally, current challenges and prospects are reviewed. Our goal was to demonstrate how these different nanocarriers can improve the therapeutic efficiency of PTX as a chemotherapeutic agent.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: